Ligand Pharmaceuticals (LGND) Insider Haas Sells 4,000 Shares

On June 12, 2026, Jason Haas, involved with Ligand Pharmaceuticals Incorporated, sold 6,461 shares of the company. The transaction was valued at approximately $1.65 million, with an average sale price of $255.58 per share. This insider sale wasn't part of a pre-planned trading program.

Insider Buying and Selling at Ligand Pharmaceuticals Incorporated

Aside from Haas, other insiders were active in June. Jason Aryeh sold 4,500 shares on June 11 and an additional 500 shares on June 10, both at $250 per share. John LaMattina also sold 4,591 shares on June 10 at a price of $250.88 per share. These transactions were not part of a planned trading scheme.

Other Institutional Activity in Ligand Pharmaceuticals

Several institutional investors made moves in Ligand Pharmaceuticals. BlackRock, Inc. increased its position by 21,692 shares, ending with 2,961,923 shares valued at about $591.35 million. Vanguard Portfolio Management LLC initiated a new position with 1,100,267 shares worth $219.67 million. Janus Henderson Group PLC boosted its holdings by 14,491 shares to 1,009,891 shares, valued at $201.62 million. Meanwhile, Invesco Ltd. significantly increased its stake by 307,140 shares, totaling 823,604 shares valued at $164.43 million.

Ligand Pharmaceuticals Incorporated Stock Down 9.7%

Shares of Ligand Pharmaceuticals (NasdaqGM:LGND) traded near $256.09. The company has a market cap of $5.12 billion and a P/E ratio of 33.27. Its beta is 1.04, indicating moderate volatility compared to the market. Over the past year, the stock has ranged from a low of $110.00 to a high of $259.03. The 50-day moving average is $226.13, while the 200-day moving average is $199.39.

Recent Earnings

Ligand Pharmaceuticals reported revenue of $274.48 million, reflecting a growth rate of 14.1%. The net margin stood at 55.95%, with a return on equity of 17.13%. Earnings per share were $7.68. The next earnings report is scheduled for August 6, 2026.

Analysts Set New Price Targets

Analysts maintain a positive stance on Ligand Pharmaceuticals. On May 8, 2026, RBC Capital reaffirmed a 'buy' rating with a price target of $262. HC Wainwright & Co. also upheld their 'buy' rating on April 30, setting a target of $289. Overall, the consensus target price is $277.60, based on 10 analyst opinions.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, headquartered in Jupiter, Florida, is a biotechnology firm that develops and licenses biopharmaceutical assets globally. The company offers treatments for infectious diseases, multiple myeloma, and other conditions. Led by CEO Todd C. Davis, Ligand employs 47 people.

Bottom Line

Insider transactions like those of Jason Haas provide insight into company sentiment but don't necessarily predict stock movement. Ligand Pharmaceuticals, with its strong market position and robust revenue growth, remains on the radar of institutional investors. Analyst ratings suggest continued confidence in the company's prospects.